Brief: Sino Biopharmaceutical Discloses Exclusive License Agreement For Rovadicitinib With Sanofi
03/03/2026 22:20
March 4 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI GROUP IS ELIGIBLE TO RECEIVE AN UPFRONT PAYMENT OF US$135 MILLION SALES MILESTONE PAYMENTS OF UP TO US$1,395 MILLION Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up